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Melphalan at a dose of 200 mg/m
2 is standard conditioning prior
to autologous hematopoietic stem cell transplantation for mul-
tiple myeloma, but a dose of 140 mg/m2 is often used in clinical
practice in patients perceived to be at risk of excess toxicity. To determine
whether melphalan 200 mg/m2 and melphalan 140 mg/m2 are equally
effective and tolerable in clinically relevant patient subgroups we ana-
lyzed 1964 first single autologous transplantation episodes using a series
of Cox proportional-hazards models. Overall survival, progression-free
survival, cumulative incidence of relapse, non-relapse mortality,
hematopoietic recovery and second primary malignancy rates were not
significantly different between the melphalan 140 mg/m2 (n=245) and
melphalan 200 mg/m2 (n=1719) groups. Multivariable subgroup analysis
showed that disease status at transplantation interacted with overall sur-
vival, progression-free survival, and cumulative incidence of relapse, with
a significant advantage associated with melphalan 200 mg/m2 in patients
transplanted in less than partial response (adjusted hazard ratios for mel-
phalan 200 mg/m2 versus melphalan 140 mg/m2: 0.5, 0.54, and 0.56). In
contrast, transplantation in very good partial or complete response signif-
icantly favored melphalan 140 mg/m2 for overall survival (adjusted haz-
ard ratio: 2.02). Age, renal function, prior proteasome inhibitor treatment,
gender, or Karnofsky score did not interact with overall/progression-free
survival or relapse rate in the melphalan dose groups. There were no sig-
nificant survival or relapse rate differences between melphalan 200
mg/m2 and melphalan 140 mg/m2 patients with high-risk or standard-risk
chromosomal abnormalities. In conclusion, remission status at the time
of transplantation may favor the use of melphalan 200 mg/m2 or melpha-
lan 140 mg/m2 for key transplant outcomes (NCT01362972).
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ABSTRACT
Introduction
High-dose chemotherapy followed by autologous
hematopoietic stem cell transplantation (ASCT) has been
the standard consolidation treatment for patients up to the
age of 65 years with newly diagnosed multiple myeloma
for over two decades. Initially, high-dose chemotherapy
plus ASCT proved superior to conventional chemothera-
py.1,2 More recently, the benefit of upfront high-dose
chemotherapy plus ASCT has been confirmed in treat-
ment approaches incorporating thalidomide analogs and
proteasome inhibitors.3-6 High-dose chemotherapy plus
ASCT is also commonly used in older patients over the
age of 65 years.7,8 However, the superiority of ASCT over
non-intensive therapies in older patients remains to be
established.9,10
In the trials that demonstrated superiority of autologous
transplantation over non-intensive approaches, patients
received high-dose chemotherapy with melphalan at a
dose of 200 mg/m2 (Mel200).1-6 Mel200 was less toxic than
other high-dose combination regimens11,12 and associated
with longer progression-free survival and overall survival
in patients younger than 60 years, when compared to mel-
phalan 100 mg/m2 in a tandem transplant approach.13
Mel200 has therefore been recommended and widely
used as standard conditioning therapy for ASCT.14-16 Some
studies have linked Mel200 to excess toxicity in older
patients and those with renal impairment.17-19
Consequently, a dose of 140 mg/m2 (Mel140) is widely
used in clinical practice in older patients and in patients
with renal impairment.20-25 However, Mel140 was associat-
ed with inferior response or survival rates compared to
Mel200 in two very recent studies.24,26 It therefore remains
to be determined whether Mel140 and Mel200 are equally
effective and tolerable across subgroups of patients.
To address this question we analyzed outcomes of
almost 2000 first single autologous transplants for multiple
myeloma after conditioning with either Mel140 or
Mel200 which were reported to the European Society for
Blood and Marrow Transplantation (EBMT). The results
of the study indicate that the selection of Mel200 versus
Mel140 may have a significant effect on key transplant
outcomes, including overall survival.
Methods
Study criteria and data management
The Collaboration to Collect Autologous Transplant Outcomes
in Lymphoma and Myeloma (CALM) study (NCT01362972) is an
observational clinical outcome analysis of a defined cohort of
patients with lymphoma or multiple myeloma who underwent
ASCT between 2008 and 2012, with data reported retrospectively
to the EBMT. Patients were eligible for the CALM study if they
were ≥18 years old and received their first autologous peripheral
blood stem cell transplant using cells mobilized with one of the
following mobilization regimens: plerixafor plus granulocyte
colony-stimulating factor (G-CSF), plerixafor plus G-CSF plus
chemotherapy, G-CSF plus chemotherapy, or G-CSF alone. For
this non-planned subgroup analysis, patients were selected from
the CALM study population in the EBMT registry if they had a
diagnosis of multiple myeloma and received a first single ASCT.
Tandem transplants (defined as an ASCT followed by a second
transplant within 6 months of the first and no relapse/progression
between the two transplants), and patients who received melpha-
lan doses other than 200 or 140 mg/m2, were not included. A total
of 2253 patients from the CALM study EBMT registry fulfilled
these general criteria. We excluded 289 of these patients from fur-
ther analysis because of missing or inconclusive data regarding
subsequent transplants (n=213), relapse date (n=67), or renal func-
tion (n=9), resulting in a final study population of 1964 patients.
The database for this study was closed on December 14, 2016. 
The study was performed in accordance with the principles of
the Declaration of Helsinki and approved by the Chronic
Malignancies Working Party of the EBMT, a non-profit scientific
society representing more than 600 transplant centers mainly
located in Europe. Data reported to the EBMT are entered, man-
aged, and maintained in a central database with internet access
housed in Leiden University Medical Center, the Netherlands.
Each EBMT center is represented in this database, and all patients
whose transplant data are reported by participating centers pro-
vide informed consent for transplant-related data to be used for
research purposes in an anonymous way.
Statistical analysis
Patients’ characteristics between the two groups (Mel140 and
Mel200) were compared using the χ2 test for categorical variables
and the Mann-Whitney test for continuous variables. P-values for
variables with more than two levels refer to an overall test for the
presence of any difference. Overall survival was defined as the
time from the date of ASCT to death from any cause. Patients still
alive were censored at their last follow up. Progression-free sur-
vival was defined as the time between transplantation and pro-
gression of disease or death, censoring patients who did not devel-
op an event.  The probabilities of overall survival and progression-
free survival were obtained using the Kaplan–Meier estimator and
comparisons were made with the log-rank test.  The probabilities
of relapse (cumulative incidence of relapse) and death without
prior relapse (non-relapse mortality) were calculated by the proper
non-parametric estimator for outcomes with competing risk and
comparisons made with the Gray test. These methods were also
used to compute the cumulative incidence of second primary
malignancy considering death without such a prior malignancy as
a competing event.
Cox proportional hazards models were used to estimate adjust-
ed hazard ratios (HR) for Mel140 compared to Mel200 in terms of
overall survival, progression-free survival and the cumulative inci-
dence of relapse. Factors included in the multivariable analysis
were age at transplant (<65 versus ≥65 years), renal function (nor-
mal glomerular filtration rate >50 mL/min versus impaired
glomerular filtration rate ≤50 mL/min), prior proteasome inhibitor
treatment (yes versus no), status of disease at transplant (complete
response/very good partial response versus partial response versus
less than partial response), Karnofsky performance score (<90 ver-
sus ≥90) and gender. Age was dichotomized with a cut-off of 65
years for comparability with other studies considering that
Martingale residuals analysis did not suggest other cut-off points
(data not shown). There was no evidence that exclusion of missing
values from multivariable analysis induced any bias in the estima-
tion of regression coefficients (data not shown).
In order to explore any possible modification of the effect of the
melphalan dose in different subgroups, we then fitted a secondary
series of Cox models. Each model included melphalan dose, the
selected adjustment variables, and the interaction between mel-
phalan dose and one of the factors. This procedure returned esti-
mated adjusted hazard ratios for Mel140 compared to Mel200 in
each subgroup defined by the selected factors, and the results are
shown in forest plots. 
Due to the partial availability of International Staging System
(ISS) and cytogenetic data, the interactions of ISS stage and chro-
Melphalan dose pre-transplant in MM
haematologica | 2018; 103(3) 515
mosomal abnormalities with melphalan dose were analyzed sep-
arately. Chromosomal abnormalities were classified as high-risk
[t(4;14), t(14;16), and del(17)] or standard risk (all other cytogenetic
findings). 
All P-values shown are from two-sided tests, and the reported
confidence intervals (CI) refer to 95% boundaries. A P-value <0.05
was regarded as statistically significant. A value up to 0.2 was used
to determine the significance of interaction terms. 
Results
Patient- and treatment-related characteristics
Patient-related and treatment characteristics are shown
in Table 1. Patients in the Mel140 group (n=245, 12.5%)
were older than patients in the Mel200 group (n=1719,
87.5%) at the time of ASCT [median 64 years (range, 27-
73) versus 59 years (range, 25-76); P<0.001]. Compared to
the Mel200 patients, those in the Mel140 group more
often had light chain myeloma, were more often in ISS III,
and were less often transplanted within 12 months of
diagnosis. The two groups differed significantly in terms
of body mass index, with a higher proportion of normal
weight patients in the Mel140 group. Mel140 patients had
received proteasome inhibitor-containing induction thera-
py more often, and a greater proportion had a Karnofsky
score of <90. Finally, more Mel140 patients had impaired
renal function, defined as a glomerular filtration rate of
≤50 mL/min, and a greater proportion of Mel140 patients
underwent ASCT in partial remission or worse. 
Efficacy 
Overall survival was not significantly different between
the two melphalan dose groups (Mel140, median not
reached; 95% CI, 70.6 months to indeterminate; Mel200,
78 months; 95% CI, 74.0 months to indeterminate) (Figure
1A). The overall adjusted hazard ratio (HR) for death from
all causes was 1.10 (95% CI: 0.79-1.54; P=0.56) for the
Mel140 group (Figure 1B). Multivariable analysis of differ-
ent subgroups showed that age, renal function, prior pro-
teasome inhibitor treatment, gender, or Karnofsky score
did not interact with overall survival in the melphalan
dose groups (Figure 1B). However, disease status at trans-
plant significantly modified the risk of death (P=0.006). In
patients transplanted in less than partial response, Mel200
was associated with a significant overall survival advan-
tage (adjusted HR 0.5 for Mel200 versus Mel140). In con-
trast, transplantation in very good partial response/com-
plete response significantly favored Mel140 (adjusted HR
2.02). Transplantation in partial response did not modify
the effect of melphalan dose on overall survival (adjusted
HR 0.98). 
The median progression-free survival was 29 months
(95% CI: 24.6-33.7) in the Mel140 group and 26.3 months
(95% CI: 24.6-28.1) in the Mel200 group (Figure 2A). The
adjusted HR for disease progression or death was 1.0
(95% CI: 0.79-1.25; P=0.98) for the Mel140 group (Figure
2B). The multivariable models with interaction terms indi-
cated that the HR of Mel200 versusMel140 was not signif-
icantly modified by age, renal function, prior proteasome
inhibitor treatment, gender, or Karnofsky score. However,
in line with the overall survival analysis, there was a sta-
tistically significant change (P=0.043) according to disease
status at transplantation. Among the patients transplanted
in partial response or less, Mel200 was associated with a
significant progression-free survival advantage (adjusted
HR 0.54 for Mel200 versus Mel140), while Mel140 was
linked to a numerically better outcome in those trans-
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Table 1. Patient- and transplant-related characteristics. 
                                                         Mel200                       Mel140           P value
Patients’ characteristics              n=1719 (87.5%)          n=245 (12.5%)            
Gender                                                                  
Male                                                        997 (58.0%)                     144 (58.8%)             0.818
Female                                                    722 (42.0%)                     101 (41.2%)                  
Age at ASCT (median and range)                  
years                                                        59 (25–76)                       64 (27–73)             0.001*
Body mass index (BMI)                                  
Underweight (BMI <18.5)                   15 (1.1%)                          4 (2.0%)               0.004*
Normal weight (18.5 ≤ BMI < 25)   484 (35.2%)                      95 (48.5%)                   
Overweight (25 ≤ BMI < 30)            587 (42.7%)                      66 (33.7%)                   
Obese (30 ≤ BMI < 35)                     216 (15.7%)                      22 (11.2%)                   
Severely obese (BMI ≥ 35)                 72 (5.2%)                          9 (4.6%)                     
Karnofsky score
≥ 90                                                        1117 (71.9%)                    139 (61.8%)            0.002*
< 90                                                         436 (28.1%)                      86 (38.2%)                   
Estimated GFR at ASCT 
>50 mL/min                                          1316 (96.3%)                    123 (63.1%)            0.001*
≤50 mL/min                                             51 (3.7%)                        72 (36.9%)                   
Myeloma characteristics                                                                                       
Myeloma type
Common type                                       1328 (78.9%)                    159 (65.7%)           0.001*
Light chain                                             328 (19.5%)                      79 (32.6%)                   
Non-secretory                                         27 (1.6%)                          4 (1.7%)                     
International Staging System stage
I                                                                453 (43.1%)                      31 (23.5%)             0.001*
II                                                               373 (35.5%)                      48 (36.4%)                   
III                                                              225 (21.4%)                      53 (40.2%)                   
High-risk chromosomal abnormalities# 
No                                                            466 (85.8%)                      78 (85.7%)              0.979
Yes                                                            77 (14.2%)                       13 (14.3%)                   
Treatment-related parameters                                                                               
Pre-transplant treatment
Alkylating agent(s)                              155 (10.6%)                        7 (3.4%)               0.001*
Alkylating agent(s)                              236 (16,2%)                      35 (17.1%)                   
+ proteasome inhibitor
Alkalyting agent(s) + IMiD(s)          322 (22.1%)                      37 (18.0%)                   
Alkylating agent(s) + proteasome    88 (6.0%)                         14 (6.8%)                    
inhibitor + IMiD(s)
Proteasome inhibitor                         233 (16.0%)                      44 (21.5%)                   
IMiD(s)                                                    92 (6.3%)                          4 (2.0%)                     
Proteasome inhibitor + IMiD(s)     280 (19.2%)                      54 (26.3%)                   
Other                                                        50 (3.4%)                         10 (4.9%)                    
Time from diagnosis to ASCT                         
< 12 months                                         1366 (79.5%)                    179 (73.1%)            0.022*
> 12 months                                          353 (20.5%)                      66 (26.9%)                   
Disease status at ASCT
CR/VGPR                                                 765 (45.2%)                     105 (43.9%)            0.020*
PR                                                            797 (47.1%)                     103 (43.1%)                  
<PR                                                          130 (7.7%)                       31 (13.0%)                   
CD34+ cells infused (per kg)
< 3 x 106                                                  405 (33.4%)                      79 (40.9%)              0.123
3 – 5 x 106                                               508 (41.9%)                      71 (36.8%)                   
> 5 x 106                                                  299 (24.7%)                      43 (22.3%)                   
*Denotes statistically significant P values (<0.05); # includes t(4;14), t(14;16), or del(17p). ASCT:
autologous stem cell transplantation; GFR: glomerular filtration rate; IMiD: immunomodulatory
drug; CR: complete response; VGPR: very good partial response; PR: partial response.
planted in very good partial response/complete response
(adjusted HR 1.19).
The cumulative incidence of relapse at 3 years was not
significantly different between the Mel140 (55.1%; 95 %
CI: 48.6-61.6) and Mel200 (59.9%; 95% CI: 57.5-62.3)
groups (Figure 3A). The adjusted HR for relapse was 0.99
(95% CI: 0.78-1.25; P=0.935) for Mel140 (Figure 3B).
Subgroup analysis again showed a significant interaction
of melphalan dose with disease status at the time of
ASCT (P=0.07), in that transplantation in partial
response or less significantly favored Mel200 (adjusted
HR 0.56 for Mel200 versus Mel140). The adjusted HR for
transplantation in partial response was 0.98 while that
for transplantation in very good partial response/com-
plete response was 1.2.
Patients with high-risk chromosomal abnormalities had
poorer overall and progression-free survival, and a higher
cumulative incidence of relapse, compared with those
with other chromosomal aberrations, but we observed no
statistically significant differences between Mel140 and
Mel200 in high-risk or standard-risk patients (Figure 4).
Similarly, while ISS stage was associated with overall and
progression-free survival, and cumulative incidence of
relapse (Online Supplementary Figure S1), there was no
interaction between melphalan dose and ISS stage (Online
Supplementary Figure S2).
Toxicity
Non-relapse mortality was not significantly different
between the Mel140 and Mel200 groups [1-year non-
relapse mortality 1.3% (95% CI: 0.0-2.7) and 0.9% (95%
CI: 0.4 – 1.3), respectively; P=0.20]. The early non-relapse
mortality rate at 3 months after ASCT was not significant-
ly different either (0.8 and 0.5%, respectively; P=0.198).
The main cause of death within 12 months of the trans-
plant was relapse/progression, being the cause in 77.8% of
patients in the Mel140 group and 80.0% of patients in the
Mel200 group. Median times to neutrophil and platelet
recovery were not significantly different between the
Mel140 and Mel200 groups, being 12 (Mel140 95% CI: 12-
13; Mel200 95% CI: 12-12) days in both groups for neu-
trophil recovery (P=0.283) and 16 (95% CI: 15-17) and 15
(95% CI: 15-16) days for platelet recovery (P=0.468).
Second primary malignancy rates 5 years after ASCT were
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Figure 1. Overall survival after autolo-
gous stem cell transplantation for
patients who received conditioning
with melphalan 140 mg/m2 (Mel140)
or 200 mg/m2 (Mel200). (A) Kaplan-
Meier curves. (B) Multivariate analyses.
The overall hazard ratio and correspon-
ding P value (bottom line) refers to the
comparison between Mel140 and
Mel200 performed in a Cox model with-
out interactions; the other hazard ratios
and P values refer to interaction terms
between melphalan dose and the indi-
cated factors. All comparisons are
adjusted for: age at transplant, renal
function, prior proteasome inhibitor
treatment, gender, status of disease,
and Karnofsky score. CR/VGPR: com-
plete response/very good partial
response; PR: partial response.
A
B
very similar between the Mel140 (4.8%; 95% CI: 1.1-8.5)
and Mel200 groups (4.8%; 95% CI: 3.6-6.0) (P=0.61). 
Discussion
While Mel200 is generally recommended as standard
conditioning prior to ASCT for multiple myeloma,27
Mel140 is often used in clinical practice in those perceived
to be at risk of excess toxicity from Mel200. However, the
effect of melphalan dose on transplant outcomes remains
undetermined. Here we present data from a large number
of patients undergoing ASCT as part of real-world treat-
ment practice. These data suggest that remission status at
the time of transplantation may favor Mel200 or Mel140
for key transplant outcomes including overall survival. 
One of the key findings of the study is that transplanta-
tion in less than partial response favored Mel200 over
Mel140 in terms of overall survival, progression-free sur-
vival, and relapse risk. This may be explained by a greater
dose-dependency of melphalan-induced anti-myeloma
effects in cells with limited chemosensitivity. However, we
observed no benefit of Mel200 over Mel140 for patients
with high-risk chromosomal aberrations or higher ISS
stage. Thus, while the better outcomes with Mel200 may
at least partly be explained by the ability of the higher dose
to overcome clinical resistance to induction therapies,
Mel200 does not overcome the effects of poor-risk cytoge-
netics or advanced ISS stage. While the number of patients
with known high-risk aberrations in our study was limited,
the findings may be considered in line with preliminary
data from an ongoing study which suggest a possible ben-
efit of tandem ASCT for high-risk patients.28 It remains to
be determined whether molecular risk profiles other than
those based on cytogenetic findings, or clinical features
such as extramedullary disease, favor Mel200.  These data
were not available for analysis in this study.
In contrast to transplantation in poor clinical responders
to induction therapy, transplantation in very good partial
response/complete response appeared to favor Mel140.
Considering that Mel200 was not linked to delayed
hematopoietic recovery, increased early or late non-
relapse mortality, or second primary malignancy rate, an
explanation for these findings is not apparent. It is con-
ceivable that Mel200 resulted in moderately increased tox-
icities that were not clinically apparent or were not cap-
tured in our study, such as delayed physical recovery, or
organ-specific toxicities such as cardiac arrhythmias.26
H.W. Auner et al.
518 haematologica | 2018; 103(3)
Figure 2. Progression-free survival after
autologous stem cell transplantation
for patients who received conditioning
with melphalan 140 mg/m2 (Mel140)
or 200 mg/m2 (Mel200). (A) Kaplan-
Meier curves. (B) Multivariate analyses.
The overall hazard ratio and correspon-
ding P value (bottom line) refers to the
comparison between Mel140 and
Mel200 performed in a Cox model with-
out interactions; the other hazard ratios
and P values refer to interaction terms
between melphalan dose and the indi-
cated factors. All comparisons are
adjusted for: age at transplant, renal
function, prior proteasome inhibitor
treatment, gender, status of disease,
and Karnofsky score. CR/VGPR: com-
plete response/very good partial
response; PR: partial response.
A
B
Such effects may have affected physicians’ and patients’
attitude towards the nature, intensity, or duration of post-
transplant treatment. However, they are not likely to fully
explain the favorable outcomes linked to Mel140 in
patients transplanted in very good partial response/com-
plete response. Differences in melphalan pharmacokinet-
ics in certain subgroups of patients may also have account-
ed for some of the effects we observed, given that diverse
factors such as creatinine clearance, fat free mass and
hematocrit influence melphalan exposure.29 Melphalan
exposure can vary considerably in myeloma patients treat-
ed with high-dose melphalan and ASCT, and higher expo-
sure has been linked to greater toxicity and better disease
responses.30 In a recent study, high melphalan exposure
was associated with significantly improved overall sur-
vival in myeloma patients undergoing ASCT.31 However,
despite the clear survival benefit, melphalan exposure was
not associated with time to progression or progression-
free survival, suggesting a possible link between melpha-
lan exposure and long-term outcomes that is not directly
attributed to immediate anti-myeloma effects.
While some studies have suggested that older age and
renal impairment can be linked to excess toxicity with
Mel200, others have not reported such an association.19,20,22-
24,26,32-34 The results of this study support the notion that
older age and impaired renal function do not favor the use
of a lower melphalan dose with regards to non-relapse
mortality, hematopoietic recovery, or second primary
malignancy rate. Moreover, we found no interaction of
Karnofsky performance score with melphalan dose.
However, the paucity in our study of data on comorbidi-
ties and frailty scores, and on the nature and grading of
specific adverse events such as mucositis, means that we
cannot exclude that Mel200 may be linked to an increase
in some toxic effects in certain patients, or that Mel140
may have avoided such effects. Nonetheless, the data pro-
vide further support for the notion that ASCT is safe and
effective in fit, older patients, and they are in line with
those of a recent study demonstrating the value of Mel140
tandem ASCT as an independent component of therapy in
older patients.35 The application of objective criteria to
determine patients’ fitness in the context of co-morbidi-
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Figure 3. Cumulative incidence of
relapse after autologous stem cell
transplantation for patients who
received conditioning with melphalan
140 mg/m2 (Mel140) or 200 mg/m2
(Mel200). (A) Kaplan-Meier curves. (B)
Multivariate analyses. The overall haz-
ard ratio and corresponding P-value
(bottom line) refers to the comparison
between Mel140 and Mel200 per-
formed in a Cox model without interac-
tions; the other hazard ratios and P val-
ues refer to interaction terms between
melphalan dose and the indicated fac-
tors. All comparisons are adjusted for:
age at transplant, renal function, prior
proteasome inhibitor treatment, gender,
status of disease, and Karnofsky score.
CR/VGPR: complete response/very
good partial response; PR: partial
response.
A
B
ties should aid optimal selection of both younger and
older patients.36-40
The CALM study is based on the retrospective analysis
of registry data that were collected in a defined cohort of
patients. Thus, the choice of Mel140 or Mel200 was made
by transplant physicians and influenced or determined by
local practice, thereby introducing a potential for biased
treatment decisions. The paucity of data on post-trans-
plant treatments, including maintenance, is another limita-
tion of the analysis. However, the large number of
patients from multiple centers across Europe is likely to
have formed a representative ‘real-world’ sample of
myeloma patients undergoing up-front ASCT. This notion
is supported by the distribution of baseline clinical and
cytogenetic features and the outcomes of patients with
high-risk compared to standard-risk disease. Moreover,
we applied robust statistical methods for the estimation of
hazard ratios. 
Our data indicate that the vast majority of patients
undergoing upfront ASCT in a real-world setting receive
Mel200 conditioning, and that patients with poor clinical
responses to induction therapies derive more benefit from
Mel200 than from Mel140. However, the results of this
study also indicate that transplantation in very good par-
tial response/complete response may favor Mel140 over
Mel200. While the reasons for this unexpected finding
remain to be determined, the data raise the challenging
question of whether more patients should receive Mel140.
This is relevant given that modern induction regimens
achieve high very good partial response/complete
response rates. The data presented here suggest that a ran-
domized trial to define the optimal melphalan dose is war-
ranted. Such a trial could also investigate the use of alter-
native conditioning approaches that incorporate novel
agents41-44 and the potential role of melphalan dosing in
tandem transplant approaches, which was not feasible in
this analysis. In the meantime, although Mel200 should
remain the standard of care for ASCT conditioning,
Mel140-based transplants could be considered as a valid
alternative to offer patients an effective combination of
ASCT plus novel therapies.45
In conclusion, our findings indicate that remission status
at the time of a first ASCT may need to be considered
when deciding the melphalan dose. 
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Figure 4. Survival and relapse risk by cytogenetic risk. (A) Overall survival, (B) progression-free survival and (C) relapse risk estimates and confidence intervals at 2
years after ASCT are shown for patients with high-risk or standard-risk chromosomal abnormalities.
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